Ask about this productRelated genes to: CKMM antibody
- Gene:
- CKM NIH gene
- Name:
- creatine kinase, M-type
- Previous symbol:
- CKMM
- Synonyms:
- -
- Chromosome:
- 19q13.32
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-02-10
Related products to: CKMM antibody
Related articles to: CKMM antibody
- The concept of cardiovascular-kidney-metabolic (CKM) syndrome integrates cardiovascular, kidney and metabolic disorders into a single pathophysiological continuum characterized by chronic inflammation, oxidative stress, fibrosis and progressive organ dysfunction. A central driver of CKM syndrome progression is inappropriate activation of the aldosterone-mineralocorticoid receptor (MR) pathway, which promotes adverse remodelling of the heart, kidney, vasculature, adipose tissue, liver and pancreas. Steroidal MR antagonists (MRAs) and non-steroidal MRAs mitigate maladaptive MR signalling and improve cardiorenal outcomes. Compared with steroidal MRAs, non-steroidal MRAs such as finerenone provide enhanced tissue selectivity and favourable safety profiles. Finerenone has been shown to reduce cardiovascular and renal events in patients with chronic kidney disease (CKD) and in patients with heart failure. Aldosterone synthase inhibitors represent a complementary approach that suppresses aldosterone production upstream of MR activation and has shown promising results in resistant hypertension and CKD. Preclinical and clinical data indicate that combined strategies targeting the aldosterone-MR axis can attenuate cardiorenal remodelling, insulin resistance and organ injury, offering a comprehensive therapeutic approach. Ongoing trials will clarify the efficacy of these combined therapies in non-diabetic CKD, resistant hypertension and broader CKM syndrome populations. Overall, targeting the aldosterone-MR pathway represents a central strategy to reduce organ dysfunction, improve metabolic homeostasis and limit progression of CKM syndrome. - Source: PubMed
Publication date: 2026/09/28
Sánchez-Bayuela TaniaBarrera-Chimal JonatanJaisser Frederic - In the US, dialysis remains the reflexive treatment option for end-stage kidney disease. Conservative kidney management (CKM), a nondialytic pathway, is infrequently utilized despite the burden dialysis often imposes on patients, caregivers, and health care systems. - Source: PubMed
Publication date: 2026/09/01
Geiger Michelle ProngDuberstein Paul RAllen Rebecca JFiscella Kevin AEpstein Ronald MSaeed Fahad - Nocturia is increasingly recognized as a manifestation of systemic cardiovascular, renal, and metabolic dysfunction, yet its prevalence and prognostic significance within the cardiovascular-kidney-metabolic (CKM) syndrome framework remain unclear. - Source: PubMed
Publication date: 2026/09/27
Xiao WeichengZhao WentanJin FengWang DongyingBao MeihuaWang JinyingLing Langping - Obesity is an important risk factor for chronic kidney disease (CKD), yet only a subset of individuals with obesity develops albuminuria, declining estimated glomerular filtration rate (eGFR), and progressive kidney disease. This variability indicates that excess body weight alone is insufficient to explain obesity-induced kidney injury. In this review, we propose that cardio-kidney-metabolic (CKM) syndrome provides a useful framework to understand this heterogeneity. We discuss major pathophysiological contributors to kidney vulnerability in obesity, including haemodynamic stress, metabolic toxicity/insulin resistance, visceral and ectopic fat, inflammation, oxidative stress, adipokine imbalance, and reduced nephron reserve. Several of these contributors converge on a common intrarenal pathway characterized by increased single-nephron workload, maladaptive glomerular hyperfiltration and intraglomerular hypertension, followed by podocyte stress, albuminuria, and progressive kidney injury. On this basis, we propose a conceptual framework comprising four overlapping CKM-related kidney vulnerability domains, which may help identify individuals at increased CKD risk, support earlier screening and longitudinal monitoring, and inform preventive strategies. - Source: PubMed
Publication date: 2026/09/26
Bozic MilicaTheodorakopoulou MarietaBevc SebastjanMiglinas MariusTrillini MatiasMorales Enrique - Cumulative exposure to atherogenic lipoproteins is increasingly recognized as a key determinant of cardiovascular-kidney-metabolic (CKM) syndrome progression. However, the association between cumulative non-high-density lipoprotein cholesterol (non-HDL-C) exposure and CKM progression remains unclear. - Source: PubMed
Publication date: 2026/09/24
Ye WenjingZhang HanrongXiao NanYang QiaoqiXue YaomingXue Junyu